Brief: Lee's Pharmaceutical Says China Oncology Focus Entered Licensing Agreement With Auransa
20/12/2018 01:21
Dec 20 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* CHINA ONCOLOGY FOCUS ENTERED LICENSING AGREEMENT GRANTING
COF
EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALISE AU018 IN CHINA
* LICENSING AGREEMENT ENTERED WITH AURANSA, INC
* COF ALSO GRANTED EXCLUSIVE RIGHTS TO DEVELOP AND
COMMERCIALISE
AU018 IN OTHER COUNTRIES OF SOUTHEAST ASIA
Source text for Eikon: urn:newsml:reuters.com:*:nHKSb61ghm
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA